Tag: as

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

WEST VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) -- The Brick is proud to announce Canadian soccer superstar Alphonso Davies as its newest brand ambassador and is celebrating the launch of the partnership with an exclusive fan meet and greet at its Park Royal location in West Vancouver on Saturday, June 20, 2026.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investors of the July 28, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.